[49] In a phase III double-blind, randomized, controlled trial supported by Eli Lilly, nondiabetic adults with a body mass index of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, were randomized to receive once-weekly, subcutaneous tirzepatide (5, 10, or 15 mg) or placebo
MEDVis program is open to adults who meet standard medical criteria for GLP-1 treatment
Does Zepbound treat sleep apnea
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
To put it into perspective, for someone weighing 240 lbs, this translates to an average loss of 33 lbs with Semaglutide, compared to 48 lbs with tirzepatide